Ectopic Pregnancy with Rising HCG After MTX (Methotrexate) Treatment? Four-Dimensional Judgment Solves the Dilemma

Having worked in gynecology clinical practice for a long time, during the combined conservative treatment of ectopic pregnancy with methotrexate (MTX), mifepristone, and traditional Chinese medicine, the most perplexing issue for me and colleagues has never been the medication regimen, but the paradoxical rise of serum human chorionic gonadotropin (HCG) 3 to 4 days after administration instead of a decline.

When patients are under hospital observation and the HCG level rises, family members feel anxious, patients panic, and they repeatedly ask if the treatment is ineffective or if immediate surgery is necessary. I also repeatedly deliberate, fearing that hasty surgery will lead to over-medicalization and violate the original intention of minimally invasive treatment to preserve fertility, as well as worrying that excessive conservative management will delay the condition and miss the optimal intervention opportunity. In fact, through years of clinical practice, I have realized that this seemingly tricky transient HCG elevation is not treatment failure, but a normal physiological process of drug efficacy. We are simply easily constrained by the "numerical-only" mindset.

From the perspective of a front-line clinician, combined with the 2023 Edition of Guidelines for the Diagnosis and Treatment of Ectopic Pregnancy and the 2024 Edition of Clinical Practice Guidelines for Ectopic Pregnancy, as well as practical clinical experience, I will elaborate on this high-frequency clinical bottleneck thoroughly. This is both a summary of my own experience and a hope to communicate, discuss, and progress with fellow colleagues.

I. Grasp the Core Principle: HCG Elevation Is Not a Bad Sign, but Drug Effect

To accurately interpret the significance of HCG changes, we must first understand the mechanism of MTX: it is not a rapid embryo-killing drug, but a trophoblast proliferation inhibitor. This is the foundation of all judgments; ignoring this point will easily lead to misdiagnosis.

In our department, for unruptured ectopic pregnancy, we always adopt a regimen of combined medication and full-course in-hospital monitoring. MTX inhibits trophoblast division, mifepristone antagonizes progesterone to cut off the nutrient supply to the lesion, and traditional Chinese medicine promotes blood circulation, removes blood stasis, and dissipates masses. The three drugs work synergistically with a clear time pattern, and HCG changes fully align with the rhythm of drug action. The elevation at 3 to 4 days is an essential critical stage:

First 3 days: Inhibition phase — Once MTX is administered, trophoblasts stop dividing rapidly, but they do not disintegrate and continue to secrete HCG normally. Thus, HCG levels either stabilize or rise slightly during this period, and patients have no obvious discomfort. This is the "foundation-laying" stage of the drug.

3 to 7 days: Release phase — This is the key stage of HCG elevation. Trophoblasts begin to apoptose and disintegrate under drug action, releasing a large amount of stored HCG into the bloodstream at once. Simply put, it is "dead cells releasing stored hormones," not the lesion growing or deteriorating. Most patients remain stable during this stage without aggravated abdominal pain or increased vaginal bleeding.

After 7 days: Decline phase — Trophoblasts are almost completely apoptotic, and no more HCG is secreted, so blood levels naturally enter a continuous downward trend. At this time, traditional Chinese medicine plays a prominent role in accelerating lesion absorption and helping HCG return to normal faster.

Multiple clinical studies and guideline data show that approximately 41.8% of patients experience mild HCG elevation 3 to 4 days after single-dose MTX treatment. Most of these patients show a decline in HCG on day 7, and the final conservative success rate is not significantly different from that of patients with immediate HCG decline after treatment. The elevation range is mostly between 1% and 15%. Therefore, whenever I see a slight increase in the value, I am confident that it is not treatment failure, but the drug working regularly.

II. A Core Method: Four-Dimensional Judgment, Do Not Only Focus on a Single Number

Panicking at the first sight of an HCG elevation report and ignoring other indicators is the most common mistake. In fact, by grasping the four dimensions of "time - amplitude - symptoms - ultrasound," we can immediately distinguish between physiological elevation and true treatment failure. All judgments are based on in-hospital observation, simple, direct, and free of hesitation. All thresholds are in line with the latest guidelines without subjective speculation.

Check time: Elevation only occurs at 3 to 4 days, and HCG decreases by ≥15% on day 7, indicating physiological elevation. If HCG continues to rise on day 7, or shows no downward trend in 3 consecutive checks every 48 hours, vigilance is required.

Check amplitude: HCG elevation ≤15% compared with the baseline before treatment without continuous upward trend is normal. If the elevation exceeds 15%, or the decline on day 7 is less than 15%, this is the treatment failure threshold clearly defined by the guidelines, requiring timely intervention.

Check symptoms: Stable vital signs, no aggravated abdominal pain, increased vaginal bleeding, or anal distension, and stable hemoglobin indicate normal conditions. If symptoms such as aggravated abdominal pain, persistent lower abdominal pain, anal distension, dizziness, and fatigue occur, the condition is abnormal and requires immediate evaluation.

Check ultrasound: Stable or slightly reduced fallopian tube mass size, no fetal heartbeat, and no increased pelvic effusion are physiological reactions. If the mass enlarges significantly, fetal heartbeat appears, or pelvic effusion increases sharply, the lesion may rupture and requires immediate treatment.

These four dimensions are complementary and indispensable. I always adhere to such comprehensive judgment in clinical practice, avoiding many misjudgments caused by a single value. The significance of in-hospital observation is to monitor these four indicators in real time, providing sufficient evidence for clinical judgments rather than making decisions based on intuition.

III. Stratified Management: Conservative When Appropriate, Operate When Necessary, No Hesitation or Abuse of Drugs

Combined with the above four-dimensional judgment, our clinical practice is actually "stratified management," all completed in the hospital. We neither perform blind surgery nor abuse drugs, nor delay the condition. This is the most practical approach summarized from years of experience, simple to implement, fully in line with guidelines, without any subjective operations.

Physiological elevation: Stick to the original regimen, no blind adjustment neededThis is the most common clinical situation, fully meeting the normal standards of four-dimensional judgment. My approach is not to add MTX, adjust mifepristone dosage, or increase traditional Chinese medicine, but to follow the original plan.

Ask the patient to stay in bed, avoid strenuous activities to reduce the risk of lesion rupture, recheck HCG every 48 hours until two consecutive declines ≥15%, perform ultrasound weekly to observe lesion absorption, and monitor vital signs throughout hospitalization. No other interventions are needed. The final conservative success rate of these patients is almost the same as that of patients with immediate HCG decline after treatment. Blind drug adjustment will only increase adverse drug reactions in patients.

Critical elevation: Salvage treatment, moderate interventionThis situation is rare: HCG rises by 15% to 20% at 3 to 4 days, and the decline on day 7 is less than 15%, but the patient has stable vital signs, no signs of rupture, and no fetal heartbeat. Salvage treatment is needed at this time, but with "minimal effective intervention" instead of aggressive medication.

My approach is to administer single-dose MTX salvage treatment (50mg/m2), continue oral mifepristone at the original dose (25mg twice daily), maintain the original traditional Chinese medicine regimen, and do not blindly increase blood-activating and stasis-removing drugs to avoid inducing bleeding. Recheck HCG on day 4 after re-administration of MTX to evaluate the downward trend, judge the treatment effect according to guideline standards, and closely monitor the condition to detect any changes promptly.

Pathological failure: Decisive surgery, laparoscopy first, no delayThis requires the most decisiveness. Once any of the following conditions occur, immediately initiate the surgical process without hesitation: HCG continues to rise by more than 20%, or no improvement after salvage treatment; aggravated abdominal pain, intra-abdominal bleeding, or even pre-shock symptoms in patients; ultrasound indicates fetal heartbeat, mass rupture, or sudden increase in pelvic effusion; or severe adverse reactions to MTX and mifepristone.

For surgery, laparoscopy is the first choice, which is the gold standard of the latest guidelines and our routine clinical operation. Laparoscopy is faster, less invasive, and more effective in hemostasis than laparotomy. For patients with fertility needs, salpingostomy is performed to preserve fertility; for those without fertility needs or with severe mass rupture, salpingectomy is performed to completely remove the lesion. Laparotomy is only considered in extreme cases where the patient is in severe shock and cannot establish pneumoperitoneum.

IV. Sincere Experience: Avoid These 4 Clinical Misconefits

After years of clinical practice, I have also taken detours and fallen into pitfalls on this issue. In summary, there are 4 most worthy clinical misconceptions about transient HCG elevation, which I share here to help fellow colleagues avoid them:

Misconception 1

Judging treatment failure and rushing for surgery as soon as HCG rises

This is the core cognitive misunderstanding. Guidelines clearly stipulate that the gold standard for effective conservative treatment of ectopic pregnancy is a ≥15% decline in HCG on day 7 after treatment, not a single value at 3 to 4 days. HCG elevation at 3 to 4 days is a normal phenomenon in nearly 40% of patients. Hasty surgery at this time is over-medicalization, which not only increases surgical trauma for patients and wastes the efficacy of combined treatment, but also violates the original intention of minimally invasive treatment to preserve fertility.

Misconception 2

Believing higher elevation means higher risk and rushing to add drugs

It is easy to fall into the misunderstanding of "higher numerical rise means more severe condition" in clinical practice, rushing to add MTX or increase traditional Chinese medicine. In fact, the trend of HCG changes is far more important than a single elevation range. I have encountered such cases in clinical practice: a patient’s HCG rose by 18% at 3 to 4 days, but dropped sharply by 35% on day 7, and finally achieved conservative success; there were also patients with only 8% elevation, but subsequent continuous HCG rise, eventually requiring surgical intervention. Do not be fooled by a single value; focusing on the 48-hour change trend is crucial. Blind drug addition will only increase the risk of liver and kidney damage in patients, not worth the loss.

Misconception 3

Blindly increasing the blood-activating intensity of traditional Chinese medicine as long as HCG rises

We always adopt integrated traditional Chinese and Western medicine treatment and deeply understand the role of traditional Chinese medicine in the conservative treatment of ectopic pregnancy, but traditional Chinese medicine is by no means a "cure-all" and cannot be used blindly. During physiological elevation, patients have no aggravated abdominal pain or increased pelvic effusion. Blindly increasing traditional Chinese medicine for promoting blood circulation, removing blood stasis, and dissipating masses at this time can easily induce intra-abdominal bleeding, which is counterproductive. Only in cases of critical elevation without surgical indications will we dialectically adjust traditional Chinese medicine to balance mass dissipation and hemostasis, which is a rational medication approach.

Misconception 4

Believing that surgery after conservative treatment failure will seriously affect fertility

This is the biggest concern of patients and their families, and also a point that needs repeated explanation in clinical practice. In fact, minimally invasive laparoscopic surgery has minimal impact on patients’ fertility. In clinical follow-up, I found that the natural pregnancy rate of patients with patent contralateral fallopian tubes after surgery is not significantly different from that of patients with successful conservative treatment. Even if patients have poor bilateral fallopian tube conditions, mature assisted reproductive technology can provide an effective way for pregnancy preparation. On the contrary, successful standardized combined conservative treatment can maximally preserve the integrity of the fallopian tube, which is more conducive to subsequent natural fertility.

Final Remarks

In gynecology clinical practice, especially in the management of ectopic pregnancy, we always seek the optimal balance between "preserving fertility" and "ensuring safety". The issue of transient HCG elevation, seemingly a clinical diagnosis and treatment bottleneck, is actually a dual test of our evidence-based thinking and clinical experience.

Guidelines provide clear diagnosis and treatment standards, in-hospital observation builds a solid safety line, and as front-line clinicians, the most important thing we should do is abandon the inherent "numerical-only" mindset and not be led by a single blood value. Supported by authoritative guidelines and clinical research, use the four-dimensional method of "time - amplitude - symptoms - ultrasound" for comprehensive judgment, firmly implement conservative treatment when appropriate, and take decisive intervention when necessary. No blindness, no hesitation, no abuse of drugs — this is not only responsible for patients, but also the core professional literacy of us clinicians.

References

[1] Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Ectopic Pregnancy (2023 Edition)[J]. Chinese Journal of Obstetrics and Gynecology, 2023, 58(6): 401-408.[2] American College of Obstetricians and Gynecologists (ACOG). Clinical Practice Guideline for Ectopic Pregnancy (2024)[J]. International Journal of Obstetrics and Gynecology, 2024, 51(2): 161-168.

Author Biography

Edited by: Qing Huan

Reviewed by: Ma Ye